Fig. 3.

Change from baseline in high-impact areas over 2 years. Data are presented for patients with plaque psoriasis initially randomized to bimekizumab (BKZ) who later entered the open-label extension (OLE). Last observation carried forward (LOCF) was used for missing data. For BKZ every 4 weeks (Q4W)/every 8 weeks (Q8W), the switch from yellow line to blue line represents the switch from BKZ 320 mg Q4W to BKZ 320 mg Q8W at Week 16. BKZ total consists of patients randomized to receive BKZ 320 mg Q4W to Week 16, and who received either BKZ Q4W or Q8W to the end of the first year (Week 48/52/56), and entered the OLE. BKZ Q4W/Q8W consists of patients randomized to BKZ 320 mg Q4W to Week 16, who received BKZ Q8W throughout the maintenance period and on OLE entry; there are no BE VIVID patients in this treatment arm. Only visits common to all the studies included in a treatment arm are presented. ^aAs a result of a lack of common visits across the studies, OLE Week 0 corresponds to Week 48 for BE SURE, BE READY, and BE RADIANT, and Week 52 for BE VIVID. BKZ bimekizumab, IGA Investigator’s Global Assessment, LOCF last observation carried forward, mNAPSI modified Nail Psoriasis Severity Index, OLE open-label extension, Q4W every 4 weeks, Q8W every 8 weeks